NEW YORK (GenomeWeb News) — 454 Life Sciences today said third-quarter revenue increased 70 percent to $9.9 million from $5.8 million year over year.
 
The CuraGen subsidiary said 454 made $4.8 million from sales of instruments and reagents and $2.8 million from sequencing service revenue. The remainder came from grants and other sources, the company said.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.